Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients

Joon Ho Moon, Sang Kyun Sohn, Shi Nae Kim, Seon Yang Park, Sung Soo Yoon, In Ho Kim, Hyeoung Joon Kim, Yeo Kyeoung Kim, Yoo Hong Min, June Won Cheong, Jinseok Kim, Chul Won Jung, Dong Hwan Kim

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

To achieve successful therapeutic outcomes in chronic myeloid leukemia (CML), continuous and adequate imatinib (Gleevec®, Glivec®, Novartis Pharmaceuticals, Basel, Switzerland) dosing is essential. Here, we report a patient counseling program ("Care club", "Happy club" in Korea) performed to improve patient compliance with imatinib. From January 2006 to December 2008, patients diagnosed with chronic phase CML and taking imatinb were eligible for this retrospective study. A total of 114 patients from 4 centers in Korea were recruited at a 50:50 ratio for Happy club group versus non-Happy club group at each center. During 36-month follow-up, persistency (the number of days of imatinib prescribed versus 1 year) was higher in the Happy club group (98.2 ± 0.03%) than in the non-Happy club group (79.3 ± 0.16%, P = 0.001), whereas dose compliance (miligrams of imatinib that were actually taken versus miligrams that should have been taken) was not different between two groups; 96.5 ± 0.6% and 96.6 ± 0.7% in the Happy club and non-Happy club (P = 0.958). Overall compliance (the product of persistency and dose compliance) improved in the Happy club group (93.0 ± 2.3%) compared with the non-Happy club group (76.2 ± 7.4%, P = 0.001). The patient counseling program was efficient especially in patients who needed high-dose imatinib (>400 mg/day), and overall compliance was 87.8 ± 6.0% in the Happy club group versus 65.5 ± 16.1% in the non-Happy club group (P = 0.017). In conclusion, the patient counseling program was effective in persisting imatinib medication, resulting in the improvement of overall compliance.

Original languageEnglish
Pages (from-to)1179-1185
Number of pages7
JournalMedical Oncology
Volume29
Issue number2
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Compliance
Counseling
Korea
Leukemia, Myeloid, Chronic Phase
Imatinib Mesylate
Patient Compliance
Switzerland
Retrospective Studies
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Moon, J. H., Sohn, S. K., Kim, S. N., Park, S. Y., Yoon, S. S., Kim, I. H., ... Kim, D. H. (2012). Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Medical Oncology, 29(2), 1179-1185. https://doi.org/10.1007/s12032-011-9926-8
Moon, Joon Ho ; Sohn, Sang Kyun ; Kim, Shi Nae ; Park, Seon Yang ; Yoon, Sung Soo ; Kim, In Ho ; Kim, Hyeoung Joon ; Kim, Yeo Kyeoung ; Min, Yoo Hong ; Cheong, June Won ; Kim, Jinseok ; Jung, Chul Won ; Kim, Dong Hwan. / Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. In: Medical Oncology. 2012 ; Vol. 29, No. 2. pp. 1179-1185.
@article{feaea2eb62cd458c8267efee8bf4a322,
title = "Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients",
abstract = "To achieve successful therapeutic outcomes in chronic myeloid leukemia (CML), continuous and adequate imatinib (Gleevec{\circledR}, Glivec{\circledR}, Novartis Pharmaceuticals, Basel, Switzerland) dosing is essential. Here, we report a patient counseling program ({"}Care club{"}, {"}Happy club{"} in Korea) performed to improve patient compliance with imatinib. From January 2006 to December 2008, patients diagnosed with chronic phase CML and taking imatinb were eligible for this retrospective study. A total of 114 patients from 4 centers in Korea were recruited at a 50:50 ratio for Happy club group versus non-Happy club group at each center. During 36-month follow-up, persistency (the number of days of imatinib prescribed versus 1 year) was higher in the Happy club group (98.2 ± 0.03{\%}) than in the non-Happy club group (79.3 ± 0.16{\%}, P = 0.001), whereas dose compliance (miligrams of imatinib that were actually taken versus miligrams that should have been taken) was not different between two groups; 96.5 ± 0.6{\%} and 96.6 ± 0.7{\%} in the Happy club and non-Happy club (P = 0.958). Overall compliance (the product of persistency and dose compliance) improved in the Happy club group (93.0 ± 2.3{\%}) compared with the non-Happy club group (76.2 ± 7.4{\%}, P = 0.001). The patient counseling program was efficient especially in patients who needed high-dose imatinib (>400 mg/day), and overall compliance was 87.8 ± 6.0{\%} in the Happy club group versus 65.5 ± 16.1{\%} in the non-Happy club group (P = 0.017). In conclusion, the patient counseling program was effective in persisting imatinib medication, resulting in the improvement of overall compliance.",
author = "Moon, {Joon Ho} and Sohn, {Sang Kyun} and Kim, {Shi Nae} and Park, {Seon Yang} and Yoon, {Sung Soo} and Kim, {In Ho} and Kim, {Hyeoung Joon} and Kim, {Yeo Kyeoung} and Min, {Yoo Hong} and Cheong, {June Won} and Jinseok Kim and Jung, {Chul Won} and Kim, {Dong Hwan}",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s12032-011-9926-8",
language = "English",
volume = "29",
pages = "1179--1185",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

Moon, JH, Sohn, SK, Kim, SN, Park, SY, Yoon, SS, Kim, IH, Kim, HJ, Kim, YK, Min, YH, Cheong, JW, Kim, J, Jung, CW & Kim, DH 2012, 'Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients', Medical Oncology, vol. 29, no. 2, pp. 1179-1185. https://doi.org/10.1007/s12032-011-9926-8

Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. / Moon, Joon Ho; Sohn, Sang Kyun; Kim, Shi Nae; Park, Seon Yang; Yoon, Sung Soo; Kim, In Ho; Kim, Hyeoung Joon; Kim, Yeo Kyeoung; Min, Yoo Hong; Cheong, June Won; Kim, Jinseok; Jung, Chul Won; Kim, Dong Hwan.

In: Medical Oncology, Vol. 29, No. 2, 01.06.2012, p. 1179-1185.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients

AU - Moon, Joon Ho

AU - Sohn, Sang Kyun

AU - Kim, Shi Nae

AU - Park, Seon Yang

AU - Yoon, Sung Soo

AU - Kim, In Ho

AU - Kim, Hyeoung Joon

AU - Kim, Yeo Kyeoung

AU - Min, Yoo Hong

AU - Cheong, June Won

AU - Kim, Jinseok

AU - Jung, Chul Won

AU - Kim, Dong Hwan

PY - 2012/6/1

Y1 - 2012/6/1

N2 - To achieve successful therapeutic outcomes in chronic myeloid leukemia (CML), continuous and adequate imatinib (Gleevec®, Glivec®, Novartis Pharmaceuticals, Basel, Switzerland) dosing is essential. Here, we report a patient counseling program ("Care club", "Happy club" in Korea) performed to improve patient compliance with imatinib. From January 2006 to December 2008, patients diagnosed with chronic phase CML and taking imatinb were eligible for this retrospective study. A total of 114 patients from 4 centers in Korea were recruited at a 50:50 ratio for Happy club group versus non-Happy club group at each center. During 36-month follow-up, persistency (the number of days of imatinib prescribed versus 1 year) was higher in the Happy club group (98.2 ± 0.03%) than in the non-Happy club group (79.3 ± 0.16%, P = 0.001), whereas dose compliance (miligrams of imatinib that were actually taken versus miligrams that should have been taken) was not different between two groups; 96.5 ± 0.6% and 96.6 ± 0.7% in the Happy club and non-Happy club (P = 0.958). Overall compliance (the product of persistency and dose compliance) improved in the Happy club group (93.0 ± 2.3%) compared with the non-Happy club group (76.2 ± 7.4%, P = 0.001). The patient counseling program was efficient especially in patients who needed high-dose imatinib (>400 mg/day), and overall compliance was 87.8 ± 6.0% in the Happy club group versus 65.5 ± 16.1% in the non-Happy club group (P = 0.017). In conclusion, the patient counseling program was effective in persisting imatinib medication, resulting in the improvement of overall compliance.

AB - To achieve successful therapeutic outcomes in chronic myeloid leukemia (CML), continuous and adequate imatinib (Gleevec®, Glivec®, Novartis Pharmaceuticals, Basel, Switzerland) dosing is essential. Here, we report a patient counseling program ("Care club", "Happy club" in Korea) performed to improve patient compliance with imatinib. From January 2006 to December 2008, patients diagnosed with chronic phase CML and taking imatinb were eligible for this retrospective study. A total of 114 patients from 4 centers in Korea were recruited at a 50:50 ratio for Happy club group versus non-Happy club group at each center. During 36-month follow-up, persistency (the number of days of imatinib prescribed versus 1 year) was higher in the Happy club group (98.2 ± 0.03%) than in the non-Happy club group (79.3 ± 0.16%, P = 0.001), whereas dose compliance (miligrams of imatinib that were actually taken versus miligrams that should have been taken) was not different between two groups; 96.5 ± 0.6% and 96.6 ± 0.7% in the Happy club and non-Happy club (P = 0.958). Overall compliance (the product of persistency and dose compliance) improved in the Happy club group (93.0 ± 2.3%) compared with the non-Happy club group (76.2 ± 7.4%, P = 0.001). The patient counseling program was efficient especially in patients who needed high-dose imatinib (>400 mg/day), and overall compliance was 87.8 ± 6.0% in the Happy club group versus 65.5 ± 16.1% in the non-Happy club group (P = 0.017). In conclusion, the patient counseling program was effective in persisting imatinib medication, resulting in the improvement of overall compliance.

UR - http://www.scopus.com/inward/record.url?scp=84866279866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866279866&partnerID=8YFLogxK

U2 - 10.1007/s12032-011-9926-8

DO - 10.1007/s12032-011-9926-8

M3 - Article

C2 - 21472487

AN - SCOPUS:84866279866

VL - 29

SP - 1179

EP - 1185

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 2

ER -